NCI National Clinical Trials Network - Network Lead Academic Participating Sites (UG1 Clinical Trial Not Allowed)

The NIH’s National Cancer Institute (NCI) invites applications for the National Clinical Trials Network (NCTN) Network Lead Academic Participating Sites (LAPS) program under RFA-CA-24-033. This opportunity, funded as a UG1 cooperative agreement, seeks institutions that can provide scientific leadership and robust patient accrual to NCTN clinical trials. Lead Academic Participating Sites are expected to collaborate with NCTN’s adult Network Groups to support and develop multi-site clinical trials in cancer research. Notably, while this funding opportunity involves leadership and participation in clinical trials, it does not allow direct support for conducting new clinical trials within the award. Eligible applicants include a range of institutions such as higher education institutions, tribal governments, local and state governments, nonprofits, for-profit organizations, and minority-serving institutions like HBCUs. Foreign organizations cannot apply directly or participate as components in these applications. With an award ceiling of $1,700,000, this program does not require cost-sharing. Applications are due by February 24, 2025, and will be archived on April 1, 2025. Detailed guidance is available in the NIH Notice of Funding Opportunity, and prospective applicants are encouraged to contact NIH for additional information. This funding opportunity is well-suited for institutions with strong capabilities in clinical research and a commitment to advancing cancer clinical trials through national collaboration.